Stocks · News reference
This marks a significant milestone in the company’s global expansion of its most advanced portable MRI technology, supporting international commercial growth and improving global access to high-quality brain imaging at
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applicationsHyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology
Read original at benzingaThis advancement is Hyperfine’s second FDA-cleared software package since the launch of its next-generation Swoop system in mid-2025. It builds on Hyperfine’s Optive AI software to deliver even higher image quality in
Read original at benzingaB. Riley Securities analyst Yuan Zhi reiterates Hyperfine (NASDAQ:HYPR) with a Buy and lowers the price target from $2 to $1.6.
Read original at benzingaHyperfine (NASDAQ:HYPR) affirms FY2026 sales outlook from $20.000 million-$22.000 million to $20.000 million-$22.000 million vs $20.163 million estimate.
Read original at benzinga